Maxwell Life Sciences - IPO

Incorporated in 2004, Maxwell Life Sciences Ltd manufactures pharmaceutical formulations for tablets, capsules, syrups, ointments, creams, liquid orals, dry syrups, and powders.

Its product portfolio comprises more than 150 formulations, including Anti-Diabetic, Anti-Psychotic, Vitamins, Minerals, Iron, Anti-Cold, Anti-Allergic, Antacid, Anti-Ulcerants, Anti-Inflammatory, Anti-Bacterial, Anti-Viral, General Antibiotics, Anti-Fungal and anti-amoebic products.

The company's manufacturing facility is located at Boisar, Maharashtra, across 1,510 square meters, with the capability to produce 180 crore tablets per year, 60 crore capsules per year, 1.80 crores bottles of syrup per year and 1.80 crores tubes of ointment per year.

Its manufacturing process is approved by the World Health organization (WHO) for Good Manufacturing Practices (GMP) and Good Laboratory process (GLP) certification issued by Food & Drugs Administration, Maharashtra.

The company supplies pharmaceutical formulations to private companies, merchant exporters, and the government contracts. Under contract manufacturing, it produces pharmaceutical formulations for private companies or parties, which then market and distribute the products under their brand names, both in the domestic and international markets.

Additionally, it also supplies medicines to government hospitals, departments, public sector units, the armed forces, and other public entities.

Competitive Strengths

• Wide range of product offerings
• Experienced promoters and management
• Scalable Business Model
• Quality assurance